MYL2 and prostate carcinoma: However, DLC1 KD1 and KD2 did not increase the levels of active RHOA-GTP and its downstream effector, phosphorylated myosin light chain 2 (p-MLC2) in melanoma cells (Fig. 2a, b), whereas elevation of RHOA activity was detected in DLC1 KD DU145 prostate cancer cells compared with the scrambled control (Supplementary Fig. 1b) consistent with previous findings [27, 28].